Jun 13, 2023 / 09:00PM GMT
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division - VP
Great. Good afternoon, everyone, and thanks to the team from Harmony. We have Jeff Dayno here, CEO recently; as well as Sandip Kapadia, who's the CFO.
And maybe we'll just start to level set, could you provide a brief overview of the company, perhaps with a particular focus on what you view as key value drivers over the next 12 to 24 months?
Jeffrey M. Dayno - Harmony Biosciences Holdings, Inc. - President, CEO & Director
Yes. Sure, Corinne. So first of all, on behalf of the Harmony team, thank you for the invitation to participate in the conference this year. So I think Harmony, basically, we are, as a little overview and background, a commercial-stage pharmaceutical company founded in 2017. We are now profitable and cash generating. And I think we're focused on developing and delivering innovative therapies for patients living with rare neurologic diseases.
Our first product, WAKIX, that is a first-in-class molecule with a novel mechanism of action, was approved in 2019
Harmony Biosciences Holdings Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers